Craft

Advanced
Galapagos

Galapagos

Stock Price

€26.8

2024-10-29

Market Capitalization

€1.8 B

2024-10-29

Revenue

€1.1 B

FY, 2025

Galapagos Summary

Company Summary

Overview
Galapagos is a biotechnology company. It specializes in the development and commercialization of small molecule medicines. The Company is engaged in pre-clinical studies and discovery programs in inflammation, fibrosis and other indications. 
Type
Public
Status
Active
Founded
1999
HQ
Mechelen, BE | view all locations
Website
http://www.glpg.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Paul Stoffels

    Paul Stoffels, Executive Director, Chair & Chief Executive Officer

    • Mary Kerr

      Mary Kerr, Non-Executive Independent Director

      • Bart Filius

        Bart Filius, President, Chief Operating Officer & Chief Financial Officer

      • Peter Guenter

        Peter Guenter, Non-Executive Independent Director

        LocationsView all

        5 locations detected

        • Mechelen, Flanders HQ

          Belgium

        • Waltham, MA

          United States

          230 CityPoint, 230 3rd Ave

        • Romainville, IDF

          France

          102 Av. Gaston Roussel

        • Leiden, ZH

          Netherlands

          Zernikedreef 16

        • Basel, BS

          Switzerland

          Aeschengraben 20

        Galapagos Financials

        Summary Financials

        Revenue (Q1, 2026)
        €6.5M
        Gross profit (Q1, 2026)
        €2.8M
        Net income (Q1, 2026)
        €13.9M
        Cash (Q1, 2026)
        €66.8M
        EBIT (Q1, 2026)
        (€63.7M)
        Enterprise value
        $1.7B

        Competitors and Similar Companies

        Compare competitors

        Footer menu

        Product

        Solutions

        Resources

        Company

        © Craft.co 2026
        Share price data provided by IEX